Clinical Trial

Novel Augmentation of DAOIB and Antioxidant for Early Dementia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Previous studies found that some NMDA-enhancing agents were able to improve cognitive function of patients with early-phase dementia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the treatment of dementia too. Whether combined treatment of an NMDA-enhancing agent and a drug with antioxidant property can be better than an NMDA-enhancing agent alone deserves study.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-06-16; most recent amendment 2026-03-18.
Status change: Not Yet Recruiting → Recruiting 2024-07-03
Trial Details
NCT Number NCT06467539
Lead Sponsor Chang Gung Memorial Hospital
Conditions Alzheimer Disease, Mild Cognitive Impairment
Enrollment 80 participants
Start Date 2024-06-19
Primary Completion 2027-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-03-19